Why a $3.5 Million Bet Targets Avantor Amid a 54% Stock Drop

1 day ago 6

Jonathan Ponciano, The Motley Fool

Sun, March 22, 2026 astatine 11:20 AM CDT 3 min read

On February 17, 2026, Circumference Group disclosed a caller presumption successful Avantor (NYSE:AVTR), acquiring 305,000 shares worthy $3.50 cardinal successful the 4th quarter.

According to a SEC filing dated February 17, 2026, Circumference Group reported establishing a caller presumption successful Avantor by acquiring 305,000 shares. The shares were worthy $3.5 cardinal astatine quarter’s end.

This caller presumption represents 3.77% of Circumference Group LLC’s 13F reportable assets arsenic of December 31, 2025.
Top holdings aft the filing:
- NYSE:TWLO: $9.25 cardinal (10.3% of AUM)
- NASDAQ:UPWK: $7.63 cardinal (8.5% of AUM)
- NASDAQ:RGP: $7.00 cardinal (7.8% of AUM)
- NYSE:PATH: $6.31 cardinal (7.0% of AUM)
- NYSE:TDC: $5.33 cardinal (5.9% of AUM)
As of Friday, shares were priced astatine $7.51, down 54% implicit the past twelvemonth and good underperforming the S&P 500, which is alternatively up astir 15% successful the aforesaid period.

Metric

Value

Revenue (TTM)	$6.55 billion
Net Income (TTM)	($530.20 million)
Market Capitalization	$5.1 billion
Price (as of Friday)	$7.51

Avantor offers a broad portfolio of laboratory materials, consumables, equipment, and specialty procurement services for biopharma, healthcare, education, precocious technologies, and applied materials sectors.
The steadfast generates gross chiefly done the merchantability of high-purity chemicals, reagents, laboratory supplies, and value-added services, including onsite laboratory enactment and biopharmaceutical improvement solutions.
It serves a planetary lawsuit basal consisting of biopharmaceutical companies, healthcare providers, world and authorities institutions, and precocious exertion firms.

Avantor, Inc. is simply a starring planetary supplier of mission-critical products and services for the beingness sciences and precocious exertion industries. The institution leverages a wide merchandise portfolio and specialized services to enactment research, production, and improvement needs crossed aggregate geographies. Avantor's scale, operational expertise, and absorption connected high-growth extremity markets underpin its competitory positioning successful the healthcare and technological proviso chain.

Moving into Avantor present mightiness marque consciousness due to the fact that the institution is generating existent currency adjacent arsenic maturation stalls, with quarterly income down 1% to $1.66 cardinal and full-year gross exceeding $6.5 billion. Profitability has declined, highlighted by a full-year nonaccomplishment owed to one-time charges, but adjusted EBITDA exceeded $1 billion, and escaped currency travel approached $500 million.

Meanwhile, this could amended with management’s “Revival” program, which aims to code execution and outgo operation issues, focusing connected go-to-market strategies and proviso concatenation improvements.

Ultimately, dissimilar high-growth biotech firms, Avantor benefits from unchangeable request for laboratory consumables and accumulation workflows, and for semipermanent investors, the cardinal volition beryllium whether margins tin retrieve without sacrificing volume; effectual execution could crook Avantor into a beardown currency generator.

Read Entire Article